| Flat View | Thursday, April 30, 2026 |
|
| August 2012 | September 2012 | October 2012 |
| Sunday, September 02, 2012 |
 |
22nd International Symposium On Medicinal Chemistry ( 8:00 am )
The Organising Committee cordially invites you to EFMC-ISMC 2012, which will be held in Berlin on September 2 - 6, 2012. It will be organised jointly by the German Chemical Society (GDCh) Division of Medicinal Chemistry and the German Pharmaceutical Society (DPhG) Section of Pharmaceutical/Medicinal Chemistry, on behalf of the European Federation for Medicinal Chemistry (EFMC). The EFMC-ISMC 2012 will continue its tradition and will cover drug discovery advances in all major therapeutic areas as well as the most recent advances in lead identification and optimization strategies, drug design and profiling technologies. Particular emphasis will be put on first time disclosures. ISMC 2012 will also illustrate the impact of the -omics and biomarker areas on the interfaces between chemistry, informatics, biology and experimental medicine.
This symposium traditionally attracts experts in drug discovery and development, in particular medicinal and synthetic chemists, together with scientists active in the fields of computer assisted drug design, biology, DMPK, pharmacology, early toxicology, as well as chemical and pharmaceutical development. It is is recognized worldwide as one of the leading Medicinal Chemistry meetings, as proven by its large international attendance.
Location: Berlin, Germany.
Contact Info : phone# 32 10 454777
Email :
Url: http://www.ismc2012.org
| |
| Monday, September 03, 2012 |
|
22nd International Symposium On Medicinal Chemistry ( 8:00 am )
The Organising Committee cordially invites you to EFMC-ISMC 2012, which will be held in Berlin on September 2 - 6, 2012. It will be organised jointly by the German Chemical Society (GDCh) Division of Medicinal Chemistry and the German Pharmaceutical Society (DPhG) Section of Pharmaceutical/Medicinal Chemistry, on behalf of the European Federation for Medicinal Chemistry (EFMC). The EFMC-ISMC 2012 will continue its tradition and will cover drug discovery advances in all major therapeutic areas as well as the most recent advances in lead identification and optimization strategies, drug design and profiling technologies. Particular emphasis will be put on first time disclosures. ISMC 2012 will also illustrate the impact of the -omics and biomarker areas on the interfaces between chemistry, informatics, biology and experimental medicine.
This symposium traditionally attracts experts in drug discovery and development, in particular medicinal and synthetic chemists, together with scientists active in the fields of computer assisted drug design, biology, DMPK, pharmacology, early toxicology, as well as chemical and pharmaceutical development. It is is recognized worldwide as one of the leading Medicinal Chemistry meetings, as proven by its large international attendance.
Location: Berlin, Germany.
Contact Info : phone# 32 10 454777
Email :
Url: http://www.ismc2012.org
| |
| Tuesday, September 04, 2012 |
|
22nd International Symposium On Medicinal Chemistry ( 8:00 am )
The Organising Committee cordially invites you to EFMC-ISMC 2012, which will be held in Berlin on September 2 - 6, 2012. It will be organised jointly by the German Chemical Society (GDCh) Division of Medicinal Chemistry and the German Pharmaceutical Society (DPhG) Section of Pharmaceutical/Medicinal Chemistry, on behalf of the European Federation for Medicinal Chemistry (EFMC). The EFMC-ISMC 2012 will continue its tradition and will cover drug discovery advances in all major therapeutic areas as well as the most recent advances in lead identification and optimization strategies, drug design and profiling technologies. Particular emphasis will be put on first time disclosures. ISMC 2012 will also illustrate the impact of the -omics and biomarker areas on the interfaces between chemistry, informatics, biology and experimental medicine.
This symposium traditionally attracts experts in drug discovery and development, in particular medicinal and synthetic chemists, together with scientists active in the fields of computer assisted drug design, biology, DMPK, pharmacology, early toxicology, as well as chemical and pharmaceutical development. It is is recognized worldwide as one of the leading Medicinal Chemistry meetings, as proven by its large international attendance.
Location: Berlin, Germany.
Contact Info : phone# 32 10 454777
Email :
Url: http://www.ismc2012.org
| |
| Wednesday, September 05, 2012 |
|
22nd International Symposium On Medicinal Chemistry ( 8:00 am )
The Organising Committee cordially invites you to EFMC-ISMC 2012, which will be held in Berlin on September 2 - 6, 2012. It will be organised jointly by the German Chemical Society (GDCh) Division of Medicinal Chemistry and the German Pharmaceutical Society (DPhG) Section of Pharmaceutical/Medicinal Chemistry, on behalf of the European Federation for Medicinal Chemistry (EFMC). The EFMC-ISMC 2012 will continue its tradition and will cover drug discovery advances in all major therapeutic areas as well as the most recent advances in lead identification and optimization strategies, drug design and profiling technologies. Particular emphasis will be put on first time disclosures. ISMC 2012 will also illustrate the impact of the -omics and biomarker areas on the interfaces between chemistry, informatics, biology and experimental medicine.
This symposium traditionally attracts experts in drug discovery and development, in particular medicinal and synthetic chemists, together with scientists active in the fields of computer assisted drug design, biology, DMPK, pharmacology, early toxicology, as well as chemical and pharmaceutical development. It is is recognized worldwide as one of the leading Medicinal Chemistry meetings, as proven by its large international attendance.
Location: Berlin, Germany.
Contact Info : phone# 32 10 454777
Email :
Url: http://www.ismc2012.org
| |
|
Crystal & Graphene Science Symposium-2012-Boston Two Theme Meetings At One Location ( 9:00 am )
GeneExpression Systems, Inc & Appasani Research
Conferences and Educational Institue (ARCEI.org)
Jontly Presents
Inaugural
Crystal & Graphene Science Symposium-2012-Boston
Two Theme Meetings at One Location
Graphene Science-2012
On
'Engineering & Applications of Fullerenes, Carbon Nanotubes & Semiconductors'
&
Crystal Science-2012
On
'Crystal Engineering to Supramolecular Chemistry & BioCrystallography'
Date: September 5 – 6, 2012
The Best Global Event in the Crystal Science !
| Expected Maximum Capacity: |
| Target Audience |
150 |
| Total Speaker Presentations: |
30 |
| Total Poster Presentations: |
10 |
| Total Exhibit Booths: |
10 |
Wednesday, Septeber 5, 2012 8:00 AM: Registration Open 9:00 AM - 6:00PM Scientific Sessions Thursday, September 6, 2012 8:00 A.M: Registration Open 9:00 AM - 6:00PM Scientific Sessions
Contact Info : GeneExpression Systems, Inc.
P.O. Box 540170
Waltham, MA 02454 USA
Tel: (781) 891-8181
Fax: (781)730-0700 or (781) 891-8234
Email :
Url: http://www.expressgenes.com
| |
|
Quantum Science Symposium-2012 ( 9:00 am )
GeneExpression Systems, Inc & Appasani Research
Conferences and Educational Institue (ARCEI.org)
Jontly Presents
Inaugural
Crystal & Graphene Science Symposium-2012-Boston
Two Theme Meetings at One Location
Graphene Science-2012
On
'Engineering & Applications of Fullerenes, Carbon Nanotubes & Semiconductors'
&
Crystal Science-2012
On
'Crystal Engineering to Supramolecular Chemistry & BioCrystallography'
Date: September 5 – 6, 2012
The Best Global Event in the Crystal Science !
| Expected Maximum Capacity: |
| Target Audience |
150 |
| Total Speaker Presentations: |
30 |
| Total Poster Presentations: |
10 |
| Total Exhibit Booths: |
10 |
Wednesday, Septeber 5, 2012 8:00 AM: Registration Open 9:00 AM - 6:00PM Scientific Sessions Thursday, September 6, 2012 8:00 A.M: Registration Open 9:00 AM - 6:00PM Scientific Sessions
Contact Info : GeneExpression Systems, Inc.
P.O. Box 540170
Waltham, MA 02454 USA
Tel: (781) 891-8181
Fax: (781)730-0700 or (781) 891-8234
Email :
Url: http://www.expressgenes.com
| |
| Thursday, September 06, 2012 |
|
22nd International Symposium On Medicinal Chemistry ( 8:00 am )
The Organising Committee cordially invites you to EFMC-ISMC 2012, which will be held in Berlin on September 2 - 6, 2012. It will be organised jointly by the German Chemical Society (GDCh) Division of Medicinal Chemistry and the German Pharmaceutical Society (DPhG) Section of Pharmaceutical/Medicinal Chemistry, on behalf of the European Federation for Medicinal Chemistry (EFMC). The EFMC-ISMC 2012 will continue its tradition and will cover drug discovery advances in all major therapeutic areas as well as the most recent advances in lead identification and optimization strategies, drug design and profiling technologies. Particular emphasis will be put on first time disclosures. ISMC 2012 will also illustrate the impact of the -omics and biomarker areas on the interfaces between chemistry, informatics, biology and experimental medicine.
This symposium traditionally attracts experts in drug discovery and development, in particular medicinal and synthetic chemists, together with scientists active in the fields of computer assisted drug design, biology, DMPK, pharmacology, early toxicology, as well as chemical and pharmaceutical development. It is is recognized worldwide as one of the leading Medicinal Chemistry meetings, as proven by its large international attendance.
Location: Berlin, Germany.
Contact Info : phone# 32 10 454777
Email :
Url: http://www.ismc2012.org
| |
|
Crystal & Graphene Science Symposium-2012-Boston Two Theme Meetings At One Location ( 9:00 am )
GeneExpression Systems, Inc & Appasani Research
Conferences and Educational Institue (ARCEI.org)
Jontly Presents
Inaugural
Crystal & Graphene Science Symposium-2012-Boston
Two Theme Meetings at One Location
Graphene Science-2012
On
'Engineering & Applications of Fullerenes, Carbon Nanotubes & Semiconductors'
&
Crystal Science-2012
On
'Crystal Engineering to Supramolecular Chemistry & BioCrystallography'
Date: September 5 – 6, 2012
The Best Global Event in the Crystal Science !
| Expected Maximum Capacity: |
| Target Audience |
150 |
| Total Speaker Presentations: |
30 |
| Total Poster Presentations: |
10 |
| Total Exhibit Booths: |
10 |
Wednesday, Septeber 5, 2012 8:00 AM: Registration Open 9:00 AM - 6:00PM Scientific Sessions Thursday, September 6, 2012 8:00 A.M: Registration Open 9:00 AM - 6:00PM Scientific Sessions
Contact Info : GeneExpression Systems, Inc.
P.O. Box 540170
Waltham, MA 02454 USA
Tel: (781) 891-8181
Fax: (781)730-0700 or (781) 891-8234
Email :
Url: http://www.expressgenes.com
| |
|
Quantum Science Symposium-2012 ( 9:00 am )
GeneExpression Systems, Inc & Appasani Research
Conferences and Educational Institue (ARCEI.org)
Jontly Presents
Inaugural
Crystal & Graphene Science Symposium-2012-Boston
Two Theme Meetings at One Location
Graphene Science-2012
On
'Engineering & Applications of Fullerenes, Carbon Nanotubes & Semiconductors'
&
Crystal Science-2012
On
'Crystal Engineering to Supramolecular Chemistry & BioCrystallography'
Date: September 5 – 6, 2012
The Best Global Event in the Crystal Science !
| Expected Maximum Capacity: |
| Target Audience |
150 |
| Total Speaker Presentations: |
30 |
| Total Poster Presentations: |
10 |
| Total Exhibit Booths: |
10 |
Wednesday, Septeber 5, 2012 8:00 AM: Registration Open 9:00 AM - 6:00PM Scientific Sessions Thursday, September 6, 2012 8:00 A.M: Registration Open 9:00 AM - 6:00PM Scientific Sessions
Contact Info : GeneExpression Systems, Inc.
P.O. Box 540170
Waltham, MA 02454 USA
Tel: (781) 891-8181
Fax: (781)730-0700 or (781) 891-8234
Email :
Url: http://www.expressgenes.com
| |
| Sunday, September 09, 2012 |
|
21st IUPAC International Conference On Physical Organic Chemistry ( 8:00 am )
The 21st IUPAC International Conference on Physical Organic Chemistry (ICPOC 21) will be organised by the RSC Physical Organic Chemistry Group. ICPOC is the leading international conference on Physical Organic Chemistry and Chemical Reactivity. The conference will consist of plenary, invited and contributed lectures, as well as poster sessions.
ICPOC-21 will bring together the organic chemistry, catalysis and physical chemistry communities from academia and industry to discuss the current state of the art, the development and future of physical organic chemistry.
Although traditionally considered as the study of mechanism, reactivity, structure and binding in organic systems, especially leading to the quantitative, molecular level understanding of their properties, physical organic chemistry nowadays also encompasses a wider range of contexts (such as biology and materials) than ever before.
If you would like to receive further information about ICPOC 21 when it is available, please email RSC Events.
Themes
* Physical Underpinnings
- dynamics in solution
- scope and limitations of trasnsitions state theory
- advances in reaction monitoring
- new approaches to aromaticity
* Mechanisms and Catalysis
- homogenous - including organo- and organometallic
- heterogenous - including nanoparticles
- mechanistic enzymology
* Supramolecular / Systems / Non-covalent interactions
- non-covalent interactions
- molecular self-assembly
- gel-forming materials
Email :
Url: http://www.rsc.org/ConferencesAndEvents/RSCConferences/icpoc21
| |
| Monday, September 10, 2012 |
|
21st IUPAC International Conference On Physical Organic Chemistry ( 8:00 am )
The 21st IUPAC International Conference on Physical Organic Chemistry (ICPOC 21) will be organised by the RSC Physical Organic Chemistry Group. ICPOC is the leading international conference on Physical Organic Chemistry and Chemical Reactivity. The conference will consist of plenary, invited and contributed lectures, as well as poster sessions.
ICPOC-21 will bring together the organic chemistry, catalysis and physical chemistry communities from academia and industry to discuss the current state of the art, the development and future of physical organic chemistry.
Although traditionally considered as the study of mechanism, reactivity, structure and binding in organic systems, especially leading to the quantitative, molecular level understanding of their properties, physical organic chemistry nowadays also encompasses a wider range of contexts (such as biology and materials) than ever before.
If you would like to receive further information about ICPOC 21 when it is available, please email RSC Events.
Themes
* Physical Underpinnings
- dynamics in solution
- scope and limitations of trasnsitions state theory
- advances in reaction monitoring
- new approaches to aromaticity
* Mechanisms and Catalysis
- homogenous - including organo- and organometallic
- heterogenous - including nanoparticles
- mechanistic enzymology
* Supramolecular / Systems / Non-covalent interactions
- non-covalent interactions
- molecular self-assembly
- gel-forming materials
Email :
Url: http://www.rsc.org/ConferencesAndEvents/RSCConferences/icpoc21
| |
|
Biomarkers In Drug Discovery & Development ( All Day )
REVOLUTIONISE YOUR DRUG DISCOVERY & DEVELOPMENT WITH BIOMARKERS
With the increase of biomarkers application since the beginning of the 21st century, we are now not only seeing a great potential in improving the efficiency and safety of drug development, but we are also coming across some barriers which may slow these processes down.
To answer the challenges connected with utilization of biomarkers, we bring together the pharmaceutical minds along with representatives from academia, research institutions and non-profit organizations.
Two focused conference days offer case studies exploiting the best practices in accelerating the identification of biomarkers, cutting the costs of attrition of compounds, reducing the size, cost and duration of clinical trials as well as the possibility of adverse events.
KEY THEMES TO BE DISCUSSED
 Exploit newest technologies for biomarker identification
Hear about latest developments in regulatory acceptance of new biomarkers
Discover best practices in speeding up your clinical trials using biomarkers
Gain knowledge about how to improve biomarker data standards, quality and reproducibility
Gain critical insight into role of biomarkers in future clinical trials
Hear case studies about successful application of biomarkers in various therapeutic areas – moving towards a personalized medicine
WHO WILL YOU MEET
Senior Vice Presidents, Chief Scientific Officers, Vice Presidents, Heads, Directors, Scientists, Researchers, Investigators, Professors in:
Biomarkers, Clinical Research, Drug Discovery and Development, Translational Research/ Science/ Imaging, Molecular Imaging, Experimental Medicine, Clinical Pharmacology, Molecular Toxicology, “Omics” Programmes, Clinical Discovery Technologies, Diagnostics, Biomarker Strategy, Assay Development, Regulatory Affairs, etc.
Contact Info : Peter Novak
Email :
| |
|
|
| Tuesday, September 11, 2012 |
|
21st IUPAC International Conference On Physical Organic Chemistry ( 8:00 am )
The 21st IUPAC International Conference on Physical Organic Chemistry (ICPOC 21) will be organised by the RSC Physical Organic Chemistry Group. ICPOC is the leading international conference on Physical Organic Chemistry and Chemical Reactivity. The conference will consist of plenary, invited and contributed lectures, as well as poster sessions.
ICPOC-21 will bring together the organic chemistry, catalysis and physical chemistry communities from academia and industry to discuss the current state of the art, the development and future of physical organic chemistry.
Although traditionally considered as the study of mechanism, reactivity, structure and binding in organic systems, especially leading to the quantitative, molecular level understanding of their properties, physical organic chemistry nowadays also encompasses a wider range of contexts (such as biology and materials) than ever before.
If you would like to receive further information about ICPOC 21 when it is available, please email RSC Events.
Themes
* Physical Underpinnings
- dynamics in solution
- scope and limitations of trasnsitions state theory
- advances in reaction monitoring
- new approaches to aromaticity
* Mechanisms and Catalysis
- homogenous - including organo- and organometallic
- heterogenous - including nanoparticles
- mechanistic enzymology
* Supramolecular / Systems / Non-covalent interactions
- non-covalent interactions
- molecular self-assembly
- gel-forming materials
Email :
Url: http://www.rsc.org/ConferencesAndEvents/RSCConferences/icpoc21
| |
|
|
|
|
| Wednesday, September 12, 2012 |
|
21st IUPAC International Conference On Physical Organic Chemistry ( 8:00 am )
The 21st IUPAC International Conference on Physical Organic Chemistry (ICPOC 21) will be organised by the RSC Physical Organic Chemistry Group. ICPOC is the leading international conference on Physical Organic Chemistry and Chemical Reactivity. The conference will consist of plenary, invited and contributed lectures, as well as poster sessions.
ICPOC-21 will bring together the organic chemistry, catalysis and physical chemistry communities from academia and industry to discuss the current state of the art, the development and future of physical organic chemistry.
Although traditionally considered as the study of mechanism, reactivity, structure and binding in organic systems, especially leading to the quantitative, molecular level understanding of their properties, physical organic chemistry nowadays also encompasses a wider range of contexts (such as biology and materials) than ever before.
If you would like to receive further information about ICPOC 21 when it is available, please email RSC Events.
Themes
* Physical Underpinnings
- dynamics in solution
- scope and limitations of trasnsitions state theory
- advances in reaction monitoring
- new approaches to aromaticity
* Mechanisms and Catalysis
- homogenous - including organo- and organometallic
- heterogenous - including nanoparticles
- mechanistic enzymology
* Supramolecular / Systems / Non-covalent interactions
- non-covalent interactions
- molecular self-assembly
- gel-forming materials
Email :
Url: http://www.rsc.org/ConferencesAndEvents/RSCConferences/icpoc21
| |
|
|
|
|
|
|
| Thursday, September 13, 2012 |
|
21st IUPAC International Conference On Physical Organic Chemistry ( 8:00 am )
The 21st IUPAC International Conference on Physical Organic Chemistry (ICPOC 21) will be organised by the RSC Physical Organic Chemistry Group. ICPOC is the leading international conference on Physical Organic Chemistry and Chemical Reactivity. The conference will consist of plenary, invited and contributed lectures, as well as poster sessions.
ICPOC-21 will bring together the organic chemistry, catalysis and physical chemistry communities from academia and industry to discuss the current state of the art, the development and future of physical organic chemistry.
Although traditionally considered as the study of mechanism, reactivity, structure and binding in organic systems, especially leading to the quantitative, molecular level understanding of their properties, physical organic chemistry nowadays also encompasses a wider range of contexts (such as biology and materials) than ever before.
If you would like to receive further information about ICPOC 21 when it is available, please email RSC Events.
Themes
* Physical Underpinnings
- dynamics in solution
- scope and limitations of trasnsitions state theory
- advances in reaction monitoring
- new approaches to aromaticity
* Mechanisms and Catalysis
- homogenous - including organo- and organometallic
- heterogenous - including nanoparticles
- mechanistic enzymology
* Supramolecular / Systems / Non-covalent interactions
- non-covalent interactions
- molecular self-assembly
- gel-forming materials
Email :
Url: http://www.rsc.org/ConferencesAndEvents/RSCConferences/icpoc21
| |
|
|
|
|
|
2nd Annual Pharma EMarketing Congress ( 8:30 am )
At this 2-day conference participants will learn about live communication and video opportunities in pharma e-detailing, understand the growing influence of the 'empowered e-patients', find out about pharma's readiness for mobile health, hear about the regulatory guidelines on industry's presence in social media, and get a grasp on useful tips on how to maximize the benefits of online communication.
Contact Info : +421 257 272 165
Email :
Url: http://pharma.flemingeurope.com/pharma-emarketing/
| |
|
|
| Friday, September 14, 2012 |
|
|
|
2nd Annual Pharma EMarketing Congress ( 8:30 am )
At this 2-day conference participants will learn about live communication and video opportunities in pharma e-detailing, understand the growing influence of the 'empowered e-patients', find out about pharma's readiness for mobile health, hear about the regulatory guidelines on industry's presence in social media, and get a grasp on useful tips on how to maximize the benefits of online communication.
Contact Info : +421 257 272 165
Email :
Url: http://pharma.flemingeurope.com/pharma-emarketing/
| |
|
|
|
|
| Saturday, September 15, 2012 |
|
2nd Annual Pharma EMarketing Congress ( 8:30 am )
At this 2-day conference participants will learn about live communication and video opportunities in pharma e-detailing, understand the growing influence of the 'empowered e-patients', find out about pharma's readiness for mobile health, hear about the regulatory guidelines on industry's presence in social media, and get a grasp on useful tips on how to maximize the benefits of online communication.
Contact Info : +421 257 272 165
Email :
Url: http://pharma.flemingeurope.com/pharma-emarketing/
| |
|
|
|
|
|
|
| Sunday, September 16, 2012 |
|
|
|
|
|
|
| Monday, September 17, 2012 |
|
|
|
|
|
|
|
Next-Generation Sequencing ( 9:00 am )
Identifying potential therapeutic drug targets and validating their suitability is a complex process involving numerous experimental platforms, including DNA sequence analysis. Since its introduction in 2005 next-generation sequencing (NGS) has fundamentally altered genomics research. Large knowledge-gaining experiments are in progress that were financially unjustifiable or even impossible five years ago. These include metagenomics to compare different disease states or patient variablility, genome sequencing of model and pathogenic species or ELT compound library screening techniques.
NGS is now successfully utilised by biopharmaceutical companies from the earliest stages of drug discovery to provide detailed genomic data and clinical applications are now emerging. These range from investigating the molecular basis of drug resistance and planning antimicrobial regimens, to vaccine development and disease diagnostics. In the rapidly growing field of personalised medicine, eight percent of medicines now have a biomarker or stratified element as compared to just a few percent five years ago.
As sequencing costs continue to fall, the future will see even faster identification of responders and non-responders, benefiting patients, prescribers and payors.
Production for the event is now underway. To discuss the progam or speak at the meeting please contact
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
.
For sponsorship and exhibition opportunities please contact
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
.
Why should you attend this event?
Join us for two days of insights and case studies from leading experts and industry executives, enabling you to:
- Generate longer nucleic acid and oligonucleotide sequences of higher quality
- Increase consensus accuracy and genome coverage
- Maximise the alignment and assembly of NGS reads with reference sequences
- Enhance signal-to-noise measurements in real-time sequencing
- Utilise exomics to elucidate gene families implicated in disease or pharmacogenetic effects
- Improve mapping in repetitive regions when resequencing
- Catalogue the transcriptomes of cells, tissues and pathogens
- Perform quantitative applications more effectively with third generation platforms
- Clarify analysis requirements prior to epigenomic studies
Hear keynote addresses from:
- Benjamin Sidders, Principal Scientist, Bioinformatician, Pfizer
- Wilhelm Ansorge, Visiting Professor, École Polytechnique Fédérale de Lausanne
Our expert speaker line-up also includes:
- Nicholas Murgolo, Fellow, Merck Research Laboratories
- Guy Cochrane, European Nucleotide Archive Team Leader, European Bioinformatics Institute
- John Marioni, Group Leader, European Bioinformatics Institute
- Michael Quail, Sequencing R&D Team Leader, The Wellcome Trust Sanger Institute
- Lisa Crossman, Microbial Genomes Project Leader, The Genome Analysis Centre
- Nicolas Fischer, Head of Research, NovImmune
- Lachlan Coin, Senior Lecturer in Statistical Genomics, Imperial College London
- Reiner Schulz, RCUK Research Fellow in Functional Genomics, King’s College London
- Guy Barker, Director, Genomics Resource Centre, University of Warwick
- Patrick Descombes, Head of Functional Genomics Core, Nestlé Institute of Health Sciences
- Irena Zaharieva, Clinical Research Associate, University College London
- Jian Han, Faculty Investigator, HudsonAlpha Institute for Biotechnology
- Alessandra Ferlini, Professor in Medical Genetics, University of Ferrara
- Mat Upton, Senior Lecturer in Medical Microbiology, University of Manchester
- Richard Bax, Senior Partner, TranScrip Partners
- Sterghios Moschos, Reader in Industrial Biotechnology, University of Westminster
- Lori Snyder, Reader in Biotechnology, Kingston University
Who should attend?
Presidents, Chief Executive Officers, Chief Scientific Officers, Chief Technology Officers, Chief Operating Officers, Vice Presidents, Directors, Professors, Heads, Program Managers and Team Leaders in:
- Genomics
- Genome Sequencing
- Sequencing Technology
- Bioinformatics
- Computational Biology
- Medical Genetics
- Clinical Genetics
- Molecular Biology
- Molecular Medicine
- Oncology
- Clinical Research & Development
- Translational Medicine
- Stratified Medicine / Personalised Medicine
- Strategic Alliances
- Business Development
Contact Info : General Enquiries:
SMi Group Ltd,
2nd Floor South, Harling House,
47-51 Great Suffolk Street,
London, SE1 0BS,
United Kingdom.
Tel: +44 (0) 20 7827 6000
Fax: +44 (0) 20 7827 6001
Client Services:
Tel: +44 (0) 870 9090 711
Fax: +44 (0) 870 9090 712
Email :
Url: http://www.smi-online.co.uk/
| |
| Tuesday, September 18, 2012 |
|
|
|
|
|
Next-Generation Sequencing ( 9:00 am )
Identifying potential therapeutic drug targets and validating their suitability is a complex process involving numerous experimental platforms, including DNA sequence analysis. Since its introduction in 2005 next-generation sequencing (NGS) has fundamentally altered genomics research. Large knowledge-gaining experiments are in progress that were financially unjustifiable or even impossible five years ago. These include metagenomics to compare different disease states or patient variablility, genome sequencing of model and pathogenic species or ELT compound library screening techniques.
NGS is now successfully utilised by biopharmaceutical companies from the earliest stages of drug discovery to provide detailed genomic data and clinical applications are now emerging. These range from investigating the molecular basis of drug resistance and planning antimicrobial regimens, to vaccine development and disease diagnostics. In the rapidly growing field of personalised medicine, eight percent of medicines now have a biomarker or stratified element as compared to just a few percent five years ago.
As sequencing costs continue to fall, the future will see even faster identification of responders and non-responders, benefiting patients, prescribers and payors.
Production for the event is now underway. To discuss the progam or speak at the meeting please contact
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
.
For sponsorship and exhibition opportunities please contact
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
.
Why should you attend this event?
Join us for two days of insights and case studies from leading experts and industry executives, enabling you to:
- Generate longer nucleic acid and oligonucleotide sequences of higher quality
- Increase consensus accuracy and genome coverage
- Maximise the alignment and assembly of NGS reads with reference sequences
- Enhance signal-to-noise measurements in real-time sequencing
- Utilise exomics to elucidate gene families implicated in disease or pharmacogenetic effects
- Improve mapping in repetitive regions when resequencing
- Catalogue the transcriptomes of cells, tissues and pathogens
- Perform quantitative applications more effectively with third generation platforms
- Clarify analysis requirements prior to epigenomic studies
Hear keynote addresses from:
- Benjamin Sidders, Principal Scientist, Bioinformatician, Pfizer
- Wilhelm Ansorge, Visiting Professor, École Polytechnique Fédérale de Lausanne
Our expert speaker line-up also includes:
- Nicholas Murgolo, Fellow, Merck Research Laboratories
- Guy Cochrane, European Nucleotide Archive Team Leader, European Bioinformatics Institute
- John Marioni, Group Leader, European Bioinformatics Institute
- Michael Quail, Sequencing R&D Team Leader, The Wellcome Trust Sanger Institute
- Lisa Crossman, Microbial Genomes Project Leader, The Genome Analysis Centre
- Nicolas Fischer, Head of Research, NovImmune
- Lachlan Coin, Senior Lecturer in Statistical Genomics, Imperial College London
- Reiner Schulz, RCUK Research Fellow in Functional Genomics, King’s College London
- Guy Barker, Director, Genomics Resource Centre, University of Warwick
- Patrick Descombes, Head of Functional Genomics Core, Nestlé Institute of Health Sciences
- Irena Zaharieva, Clinical Research Associate, University College London
- Jian Han, Faculty Investigator, HudsonAlpha Institute for Biotechnology
- Alessandra Ferlini, Professor in Medical Genetics, University of Ferrara
- Mat Upton, Senior Lecturer in Medical Microbiology, University of Manchester
- Richard Bax, Senior Partner, TranScrip Partners
- Sterghios Moschos, Reader in Industrial Biotechnology, University of Westminster
- Lori Snyder, Reader in Biotechnology, Kingston University
Who should attend?
Presidents, Chief Executive Officers, Chief Scientific Officers, Chief Technology Officers, Chief Operating Officers, Vice Presidents, Directors, Professors, Heads, Program Managers and Team Leaders in:
- Genomics
- Genome Sequencing
- Sequencing Technology
- Bioinformatics
- Computational Biology
- Medical Genetics
- Clinical Genetics
- Molecular Biology
- Molecular Medicine
- Oncology
- Clinical Research & Development
- Translational Medicine
- Stratified Medicine / Personalised Medicine
- Strategic Alliances
- Business Development
Contact Info : General Enquiries:
SMi Group Ltd,
2nd Floor South, Harling House,
47-51 Great Suffolk Street,
London, SE1 0BS,
United Kingdom.
Tel: +44 (0) 20 7827 6000
Fax: +44 (0) 20 7827 6001
Client Services:
Tel: +44 (0) 870 9090 711
Fax: +44 (0) 870 9090 712
Email :
Url: http://www.smi-online.co.uk/
| |
|
|
| Wednesday, September 19, 2012 |
|
|
|
|
|
|
|
Cancer Vaccines ( 9:00 am )
SMi is proud to present their inaugural conference...
Cancer Vaccines 2012
19th & 20th September 2012, London
|
SMi's inaugural conference on Cancer Vaccines will provide attendees with a complete view of the cancer immunotherapy field. Focusing on the discovery of new vaccines, developments in target identification and vaccine delivery strategies, this informative event will bring together key opinion leaders in the field to provide attendees with an indepth look into current advances in cancer vaccines.
The event will present itself as a perfect forum for learning about new advances in the field, presenting attendees with the latest information on technogical and regulatory updates in the field. SMi's Cancer Vaccines 2012 will explore the use of biomarkers in cancer immunotherapy developments and will provide the perfect platform for discussions into regulatory challenges faced in cancer developments as well as strategies to improve success in clinical trials.
With senior industry representatives presenting on their own exepriences and referring to case studies, success stories and failures, this event promises to be a unique forum for problem-solving debate and idea-sharing discussion.
Interested in speaking at the conference? Contact the Conference Producer.
For sponsorship and exhibition opportunities, Contact our Sponsorship Department
|
 |
Why should you attend this event?
 |
• Learn about and consider the issues within novel vaccine discovery
• Discuss methods and strategies for efficient target selection
• Consider developments in vaccine delivery strategies
• Understand the use of biomarkers in cancer immunotherapy
• Debate the importance of overcoming immune supression in the tumor microenvironment
• Evaluate manufacturing, regulatory and commercial challenges
• Develop ideas and network with key industry professionals
|
Hear keynote addresses from:
Our Expert Speaker Line-up includes:
Vincent Brichard, Senior Vice President, GSK Biologicals
Oliver Wilbert, Senior Director, Merck-Serono
Nicholas Valiante, Head of Immunology, Novartis
Jerome Galon, Director of Research, INSERM
Sonia Quaratino, Senior Medical Director, Merck-Serono
Athansios Papadopoulos, Senior Medical Advisor, Novartis
Matthew Albert, Director of Immunology, Institut Pasteur
Philip Ashton-Rickardt, Chair in Immunology, Imperial College London
Karl-Josef Kallen, Chief Scientific Officer, CureVac
Eric Leire, CEO, DanDrit Biotech
Christian Ottensmeier, Professor in Experimental Cancer Medicine, University of Southampton
Rohit Lal, Consultant Oncologist, Guy's Hospital
Contact Info : General Enquiries:
SMi Group Ltd,
2nd Floor South, Harling House,
47-51 Great Suffolk Street,
London, SE1 0BS,
United Kingdom.
Tel: +44 (0) 20 7827 6000
Fax: +44 (0) 20 7827 6001
Client Services:
Tel: +44 (0) 870 9090 711
Fax: +44 (0) 870 9090 712
Email :
Url: http://www.smi-online.co.uk
| |
| Thursday, September 20, 2012 |
|
|
|
|
|
Cancer Vaccines ( 9:00 am )
SMi is proud to present their inaugural conference...
Cancer Vaccines 2012
19th & 20th September 2012, London
|
SMi's inaugural conference on Cancer Vaccines will provide attendees with a complete view of the cancer immunotherapy field. Focusing on the discovery of new vaccines, developments in target identification and vaccine delivery strategies, this informative event will bring together key opinion leaders in the field to provide attendees with an indepth look into current advances in cancer vaccines.
The event will present itself as a perfect forum for learning about new advances in the field, presenting attendees with the latest information on technogical and regulatory updates in the field. SMi's Cancer Vaccines 2012 will explore the use of biomarkers in cancer immunotherapy developments and will provide the perfect platform for discussions into regulatory challenges faced in cancer developments as well as strategies to improve success in clinical trials.
With senior industry representatives presenting on their own exepriences and referring to case studies, success stories and failures, this event promises to be a unique forum for problem-solving debate and idea-sharing discussion.
Interested in speaking at the conference? Contact the Conference Producer.
For sponsorship and exhibition opportunities, Contact our Sponsorship Department
|
|
Why should you attend this event?
|
• Learn about and consider the issues within novel vaccine discovery
• Discuss methods and strategies for efficient target selection
• Consider developments in vaccine delivery strategies
• Understand the use of biomarkers in cancer immunotherapy
• Debate the importance of overcoming immune supression in the tumor microenvironment
• Evaluate manufacturing, regulatory and commercial challenges
• Develop ideas and network with key industry professionals
|
Hear keynote addresses from:
Our Expert Speaker Line-up includes:
Vincent Brichard, Senior Vice President, GSK Biologicals
Oliver Wilbert, Senior Director, Merck-Serono
Nicholas Valiante, Head of Immunology, Novartis
Jerome Galon, Director of Research, INSERM
Sonia Quaratino, Senior Medical Director, Merck-Serono
Athansios Papadopoulos, Senior Medical Advisor, Novartis
Matthew Albert, Director of Immunology, Institut Pasteur
Philip Ashton-Rickardt, Chair in Immunology, Imperial College London
Karl-Josef Kallen, Chief Scientific Officer, CureVac
Eric Leire, CEO, DanDrit Biotech
Christian Ottensmeier, Professor in Experimental Cancer Medicine, University of Southampton
Rohit Lal, Consultant Oncologist, Guy's Hospital
Contact Info : General Enquiries:
SMi Group Ltd,
2nd Floor South, Harling House,
47-51 Great Suffolk Street,
London, SE1 0BS,
United Kingdom.
Tel: +44 (0) 20 7827 6000
Fax: +44 (0) 20 7827 6001
Client Services:
Tel: +44 (0) 870 9090 711
Fax: +44 (0) 870 9090 712
Email :
Url: http://www.smi-online.co.uk
| |
|
|
| Friday, September 21, 2012 |
|
|
|
|
|
|
| Saturday, September 22, 2012 |
|
|
|
|
|
|
| Sunday, September 23, 2012 |
|
|
|
|
|
International Symposium On Catalysis And Speciality Chemicals (ISCSC 2012) ( 8:00 am )
The symposium aims to provide a platform for scientists, researchers, academicians as well as industry professionals from all over the world to present their recent research results and development activities in the fields of catalysis, petrochemistry, clean energies and all useful materials and chemicals developed in the spirit of green chemistry. The scientific program will include plenary and keynote lectures, oral presentations and posters. We invite you to contribute and enrich the discussions by submitting your recent results to ISCSC 2012.
Topics: Symposium main topics include (but are not limited to) :
Topic 1 : Catalysis and Petrochemistry
* Acid-Base Catalysis
* Application to Refining
* Aliphatic Charge Transformation
* Olefin Oligo- & Polymerization
Topic 2 : Catalysts for Cleaner Energies
* Hydrogen Technologies & Fuel Cells
* Biomass Transformations
* Biofuels
* Catalysts for air cleaning
* Catalyts for water cleaning
Topic 3 : Nanomaterials in Catalysis
* Advanced Synthesis
* Hybride and Composite Materials
* New Applications
Topic 4 : Intermediates in Green Chemistry
* Product Design
* Green Solvents for Chemical Synthesis
* Green Routes for Chemical Synthesis
* Biotransformations and Bioproducts
Topic 5 : Catalysis for Fine Chemicals and Pharmaceuticals
Contact Info : Dr. Sumeya M. Bedrane
Email :
Url: http://iscsc.univ-tlemcen.dz
| |
|
|
| Monday, September 24, 2012 |
|
|
|
International Symposium On Catalysis And Speciality Chemicals (ISCSC 2012) ( 8:00 am )
The symposium aims to provide a platform for scientists, researchers, academicians as well as industry professionals from all over the world to present their recent research results and development activities in the fields of catalysis, petrochemistry, clean energies and all useful materials and chemicals developed in the spirit of green chemistry. The scientific program will include plenary and keynote lectures, oral presentations and posters. We invite you to contribute and enrich the discussions by submitting your recent results to ISCSC 2012.
Topics: Symposium main topics include (but are not limited to) :
Topic 1 : Catalysis and Petrochemistry
* Acid-Base Catalysis
* Application to Refining
* Aliphatic Charge Transformation
* Olefin Oligo- & Polymerization
Topic 2 : Catalysts for Cleaner Energies
* Hydrogen Technologies & Fuel Cells
* Biomass Transformations
* Biofuels
* Catalysts for air cleaning
* Catalyts for water cleaning
Topic 3 : Nanomaterials in Catalysis
* Advanced Synthesis
* Hybride and Composite Materials
* New Applications
Topic 4 : Intermediates in Green Chemistry
* Product Design
* Green Solvents for Chemical Synthesis
* Green Routes for Chemical Synthesis
* Biotransformations and Bioproducts
Topic 5 : Catalysis for Fine Chemicals and Pharmaceuticals
Contact Info : Dr. Sumeya M. Bedrane
Email :
Url: http://iscsc.univ-tlemcen.dz
| |
|
|
|
10th Annual Cold Chain & Temperature Management Global Forum ( All Day )
We are excited to bring you the 10th Anniversary special of the annual Cold Chain & Temperature Management Global Forum (http://www.coldchainpharma.com) taking place from September 24 - 28, 2012. To celebrate, we are moving to the Chicago Hyatt Regency McCormick Place, you spoke and we listened!
In today’s complex supply chain, constantly evolving regulations, technology developments and cost pressures require the most up to date information, a reality for Supply Chain Healthcare professionals. Join us to learn about the leading solutions, strategies and regulations in temperature controlled distribution from around the world.
The 2012 Global Forum will reflect key challenges in the market and bring you peer-to-peer experiences, networking and hard-hitting new information on overcoming the most pressing issues facing temperature control logistics and QA professionals today.
Email :
Url: http://www.coldchainpharma.com
| |
|
|
|
Biosimilars And Biobetters ( 9:00 am )
 Following the success of our past events, SMi’s third Biosimilars and Biobetters conference will build upon the progress made in previous meetings and further develop the ideas and strategies that were debated and discussed. In particular how industry players will face regulatory challenges in approval of follow on biologics, rising development costs, threat from competition and a similar if not bigger challenge to that seen in marketing of innovator drugs.
There will be case studies from those who are both developing and distributing follow on biologics. With analysis of key trends in biologic pipelines, methods in clinical trials for biosimilar approval, a review of emerging markets, assessment of biosimilar manufacturing, post approval strategy and future forecasting for follow on biologics.
SMi’s Biosimilars and Biobetters event will provide up to date information from key opinion leaders in the biologics industry with discussion and debate and opportunities for networking between CROs, CMOs, law firms, regulatory bodies, pharma and biotechs.
If you are interested in speaking at the conference, please contact
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
For sponsorship and exhibition opportunities, please contact
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Why should you attend this event?
|
Hear talks from key opinion leaders on regulatory issues, pipelines, emerging markets, manufacturing and distribution
Witness a strong focus on pioneering topics that will expose commercial opportunities for future investments
Recieve in depth analysis of the biosimilars market relevant to buyers and sellers alike
Experience a platform for networking between solution providers, pharma and biotechs
Be part of real progress towards the future of accessible medicines and partake in discussion about key developments important to all with a vested interest in follow on biologics
|
Hear keynote addresses from:
Laura McKinley, Director Worldwide Regulatory Strategy, Pfizer
Paul Greenland, EMEA Director of Biosimilars and Proprietary Marketing, Hospira
Andrew Rankin, Head of Clinical Development, Teva Pharmaceuticals
Our expert speaker line-up also includes:
Sreedhar Sagi, Risk Management Compliance Officer Biopharmaceuticals Development, Sandoz
Richard DiCicco, Chairman, Harvest Moon Pharmaceuticals USA, Inc
Anne Dollard, Chief Patent Counsel, Deputy General Counsel, Takeda Pharmaceuticals
Sandy Eisen, Chief Medical Officer, former CMO, Frontline Pharma Consulting, Teva Pharmaceuticals
David Szymkowski, Senior Director, Research, Biotherapeutics, Xencor, Inc
Steve Brocchini, CSO, PolyTherics Ltd.
Nicola Travierso, General Manager, NTC SRL
Christopher Stothers, Partner, Arnold and Porter LLP
Peter Wittner, Senior Consultant, Interpharm Consultancy
Ori Hershkovitz, Partner and Head of Pharmaceutical Research, Sphera Global Healthcare Fund
Contact Info : General Enquiries:
SMi Group Ltd,
2nd Floor South, Harling House,
47-51 Great Suffolk Street,
London, SE1 0BS,
United Kingdom.
Tel: +44 (0) 20 7827 6000
Fax: +44 (0) 20 7827 6001
Client Services:
Tel: +44 (0) 870 9090 711
Fax: +44 (0) 870 9090 712
Email :
Url: http://www.smi-online.co.uk
| |
| Tuesday, September 25, 2012 |
|
International Symposium On Catalysis And Speciality Chemicals (ISCSC 2012) ( 8:00 am )
The symposium aims to provide a platform for scientists, researchers, academicians as well as industry professionals from all over the world to present their recent research results and development activities in the fields of catalysis, petrochemistry, clean energies and all useful materials and chemicals developed in the spirit of green chemistry. The scientific program will include plenary and keynote lectures, oral presentations and posters. We invite you to contribute and enrich the discussions by submitting your recent results to ISCSC 2012.
Topics: Symposium main topics include (but are not limited to) :
Topic 1 : Catalysis and Petrochemistry
* Acid-Base Catalysis
* Application to Refining
* Aliphatic Charge Transformation
* Olefin Oligo- & Polymerization
Topic 2 : Catalysts for Cleaner Energies
* Hydrogen Technologies & Fuel Cells
* Biomass Transformations
* Biofuels
* Catalysts for air cleaning
* Catalyts for water cleaning
Topic 3 : Nanomaterials in Catalysis
* Advanced Synthesis
* Hybride and Composite Materials
* New Applications
Topic 4 : Intermediates in Green Chemistry
* Product Design
* Green Solvents for Chemical Synthesis
* Green Routes for Chemical Synthesis
* Biotransformations and Bioproducts
Topic 5 : Catalysis for Fine Chemicals and Pharmaceuticals
Contact Info : Dr. Sumeya M. Bedrane
Email :
Url: http://iscsc.univ-tlemcen.dz
| |
|
|
|
|
|
Biosimilars And Biobetters ( 9:00 am )
Following the success of our past events, SMi’s third Biosimilars and Biobetters conference will build upon the progress made in previous meetings and further develop the ideas and strategies that were debated and discussed. In particular how industry players will face regulatory challenges in approval of follow on biologics, rising development costs, threat from competition and a similar if not bigger challenge to that seen in marketing of innovator drugs.
There will be case studies from those who are both developing and distributing follow on biologics. With analysis of key trends in biologic pipelines, methods in clinical trials for biosimilar approval, a review of emerging markets, assessment of biosimilar manufacturing, post approval strategy and future forecasting for follow on biologics.
SMi’s Biosimilars and Biobetters event will provide up to date information from key opinion leaders in the biologics industry with discussion and debate and opportunities for networking between CROs, CMOs, law firms, regulatory bodies, pharma and biotechs.
If you are interested in speaking at the conference, please contact
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
For sponsorship and exhibition opportunities, please contact
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Why should you attend this event?
|
Hear talks from key opinion leaders on regulatory issues, pipelines, emerging markets, manufacturing and distribution
Witness a strong focus on pioneering topics that will expose commercial opportunities for future investments
Recieve in depth analysis of the biosimilars market relevant to buyers and sellers alike
Experience a platform for networking between solution providers, pharma and biotechs
Be part of real progress towards the future of accessible medicines and partake in discussion about key developments important to all with a vested interest in follow on biologics
|
Hear keynote addresses from:
Laura McKinley, Director Worldwide Regulatory Strategy, Pfizer
Paul Greenland, EMEA Director of Biosimilars and Proprietary Marketing, Hospira
Andrew Rankin, Head of Clinical Development, Teva Pharmaceuticals
Our expert speaker line-up also includes:
Sreedhar Sagi, Risk Management Compliance Officer Biopharmaceuticals Development, Sandoz
Richard DiCicco, Chairman, Harvest Moon Pharmaceuticals USA, Inc
Anne Dollard, Chief Patent Counsel, Deputy General Counsel, Takeda Pharmaceuticals
Sandy Eisen, Chief Medical Officer, former CMO, Frontline Pharma Consulting, Teva Pharmaceuticals
David Szymkowski, Senior Director, Research, Biotherapeutics, Xencor, Inc
Steve Brocchini, CSO, PolyTherics Ltd.
Nicola Travierso, General Manager, NTC SRL
Christopher Stothers, Partner, Arnold and Porter LLP
Peter Wittner, Senior Consultant, Interpharm Consultancy
Ori Hershkovitz, Partner and Head of Pharmaceutical Research, Sphera Global Healthcare Fund
Contact Info : General Enquiries:
SMi Group Ltd,
2nd Floor South, Harling House,
47-51 Great Suffolk Street,
London, SE1 0BS,
United Kingdom.
Tel: +44 (0) 20 7827 6000
Fax: +44 (0) 20 7827 6001
Client Services:
Tel: +44 (0) 870 9090 711
Fax: +44 (0) 870 9090 712
Email :
Url: http://www.smi-online.co.uk
| |
|
|
| Wednesday, September 26, 2012 |
|
International Symposium On Catalysis And Speciality Chemicals (ISCSC 2012) ( 8:00 am )
The symposium aims to provide a platform for scientists, researchers, academicians as well as industry professionals from all over the world to present their recent research results and development activities in the fields of catalysis, petrochemistry, clean energies and all useful materials and chemicals developed in the spirit of green chemistry. The scientific program will include plenary and keynote lectures, oral presentations and posters. We invite you to contribute and enrich the discussions by submitting your recent results to ISCSC 2012.
Topics: Symposium main topics include (but are not limited to) :
Topic 1 : Catalysis and Petrochemistry
* Acid-Base Catalysis
* Application to Refining
* Aliphatic Charge Transformation
* Olefin Oligo- & Polymerization
Topic 2 : Catalysts for Cleaner Energies
* Hydrogen Technologies & Fuel Cells
* Biomass Transformations
* Biofuels
* Catalysts for air cleaning
* Catalyts for water cleaning
Topic 3 : Nanomaterials in Catalysis
* Advanced Synthesis
* Hybride and Composite Materials
* New Applications
Topic 4 : Intermediates in Green Chemistry
* Product Design
* Green Solvents for Chemical Synthesis
* Green Routes for Chemical Synthesis
* Biotransformations and Bioproducts
Topic 5 : Catalysis for Fine Chemicals and Pharmaceuticals
Contact Info : Dr. Sumeya M. Bedrane
Email :
Url: http://iscsc.univ-tlemcen.dz
| |
|
|
|
|
|
|
|
KOL Management ( 9:00 am )
|
As a pharmaceutical/healthcare professional, you know how valuable KOLs are to your organisation and how they contribute to the success of your clinical research. In today's competitive and challenging market, it is vital that relationship between the pharmaceutical/healthcare industry and KOLs are not only built but nurtured and maintained.
Identifying and engaging KOLs for your organisation is crucial to the success of your product. Entering European markets is a challenge faced by the pharmaceutical industry with ever-changing pricing structures and regulations. Working closely and adopting a culture of transparent collaboration and engagement with KOLs helps overcome some of these challenges.
SMi is proud to present KOL Knowledge Leaders focussed to keepour audience up-to-date with developments in the ever-changing KOL sphere.
|
 |
Why should you attend this event?
Hear about all the latest regulatory guidance in the European markets
Identify and engage with KOL through effective social media and traditional channels
Gain an insight into current transparent and flexible relationships
Improve your relationship with key leaders
Overcoming cultural barriers and dealing with change management
Establishing the return on investment for your KOL and MSL management
Develop a successful KOL management program
Hear keynote addresses from:
Confirmed chairs:
• Simon Twigden, Team Leader, Special Projects, Bayer
• David Gillen, Medical Director, Celgene
Confirmed KOLs:
• Audrey Craven, President, European Federation of Neurological Associations (EFNA)
• Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
• Mario Ottiglio, Associate Director, Public Affairs & Global Health Policy, IFPMA
• Charles Alessi, Chairman, National Association of Primary Care (NAPC)
• Susanna Palkonen, Executive Officer, European Federation of Allergy and Airways Diseases Patients Associations
• Prof Wisia Wedzicha, Professor Respiratory Medicine, University College London
Confirmed speakers:
• Michal Konstacky, Medical Affairs Director, Takeda
• Ales Kminek, Medical Marketing Director, AstraZeneca
• Christian Felter, Senior Director, Medical Affairs, Astellas Pharma
• Sanjita Panchal, Medical Scientific Liaison, Merck
• Shaul Brazil, Barrister, BCL Burton Copeland
• Keith Allan, Head of Global Advocacy, Novartis
• Lurdes Reis, Marketing Manager, Bayer
• David Gillen, Medical Director, Celgene
• Philippe Fonjallaz, Medical Affairs, Merck Serono
• Neil Ranasinghe, Medical Sciences Manager, Oncology, Immunology & Neuroscience, Bristol-Myers Squibb
Confirmed joint presentation with KOL:
• Johanna Jarvis, Managing Director, Jarvis Consulting & Tim Curry, Assistant Head of Nursing, Royal College of Nursing
• Miriam George, CEO, PDC Healthcare & Raman Aulakh, Director, The Ashcroft Clinic - Private Hospital Facility
Contact Info : General Enquiries:
SMi Group Ltd,
2nd Floor South, Harling House,
47-51 Great Suffolk Street,
London, SE1 0BS,
United Kingdom.
Tel: +44 (0) 20 7827 6000
Fax: +44 (0) 20 7827 6001
Client Services:
Tel: +44 (0) 870 9090 711
Fax: +44 (0) 870 9090 712
Email :
Url: http://www.smi-online.co.uk/
| |
| Thursday, September 27, 2012 |
|
|
|
|
|
KOL Management ( 9:00 am )
|
As a pharmaceutical/healthcare professional, you know how valuable KOLs are to your organisation and how they contribute to the success of your clinical research. In today's competitive and challenging market, it is vital that relationship between the pharmaceutical/healthcare industry and KOLs are not only built but nurtured and maintained.
Identifying and engaging KOLs for your organisation is crucial to the success of your product. Entering European markets is a challenge faced by the pharmaceutical industry with ever-changing pricing structures and regulations. Working closely and adopting a culture of transparent collaboration and engagement with KOLs helps overcome some of these challenges.
SMi is proud to present KOL Knowledge Leaders focussed to keepour audience up-to-date with developments in the ever-changing KOL sphere.
|
|
Why should you attend this event?
Hear about all the latest regulatory guidance in the European markets
Identify and engage with KOL through effective social media and traditional channels
Gain an insight into current transparent and flexible relationships
Improve your relationship with key leaders
Overcoming cultural barriers and dealing with change management
Establishing the return on investment for your KOL and MSL management
Develop a successful KOL management program
Hear keynote addresses from:
Confirmed chairs:
• Simon Twigden, Team Leader, Special Projects, Bayer
• David Gillen, Medical Director, Celgene
Confirmed KOLs:
• Audrey Craven, President, European Federation of Neurological Associations (EFNA)
• Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
• Mario Ottiglio, Associate Director, Public Affairs & Global Health Policy, IFPMA
• Charles Alessi, Chairman, National Association of Primary Care (NAPC)
• Susanna Palkonen, Executive Officer, European Federation of Allergy and Airways Diseases Patients Associations
• Prof Wisia Wedzicha, Professor Respiratory Medicine, University College London
Confirmed speakers:
• Michal Konstacky, Medical Affairs Director, Takeda
• Ales Kminek, Medical Marketing Director, AstraZeneca
• Christian Felter, Senior Director, Medical Affairs, Astellas Pharma
• Sanjita Panchal, Medical Scientific Liaison, Merck
• Shaul Brazil, Barrister, BCL Burton Copeland
• Keith Allan, Head of Global Advocacy, Novartis
• Lurdes Reis, Marketing Manager, Bayer
• David Gillen, Medical Director, Celgene
• Philippe Fonjallaz, Medical Affairs, Merck Serono
• Neil Ranasinghe, Medical Sciences Manager, Oncology, Immunology & Neuroscience, Bristol-Myers Squibb
Confirmed joint presentation with KOL:
• Johanna Jarvis, Managing Director, Jarvis Consulting & Tim Curry, Assistant Head of Nursing, Royal College of Nursing
• Miriam George, CEO, PDC Healthcare & Raman Aulakh, Director, The Ashcroft Clinic - Private Hospital Facility
Contact Info : General Enquiries:
SMi Group Ltd,
2nd Floor South, Harling House,
47-51 Great Suffolk Street,
London, SE1 0BS,
United Kingdom.
Tel: +44 (0) 20 7827 6000
Fax: +44 (0) 20 7827 6001
Client Services:
Tel: +44 (0) 870 9090 711
Fax: +44 (0) 870 9090 712
Email :
Url: http://www.smi-online.co.uk/
| |
|
|
| Friday, September 28, 2012 |
|
|
|
|
|
|
| Saturday, September 29, 2012 |
|
|
|
|
|
|
| Sunday, September 30, 2012 |
|
|
|
|
|
|
|
|
